Work

Sustained remission of severe multicentric castleman disease following multiagent chemotherapy and tocilizumab maintenance

Year: 2013

Type: article

Abstract: Castleman disease is a rare lymphoproliferative disorder, which presents in a unicentric or multicentric fashion. Multicentric Castleman disease (MCD) is associated with significant systemic symptoms, in part related to the underlying role of interleukin-6 in disease pathogenesis. Treatment for MCD has not been well established and prognosis has historically been poor. We present a case of severe MCD in a pediatric patient who has shown sustained remission following multi-agent chemotherapy and targeted maintenance therapy with the interleukin-6 receptor inhibitor, tocilizumab. This represents the first case report of sustained remission of MCD in a pediatric patient following discontinuation of tocilizumab therapy.

Source: Pediatric Blood & Cancer

DOI: 10.1002/pbc.24761

Authors: Lucie M. Turcotte, Colleen K. Correll, Robyn C. Reed, Christopher L. Moertel

Institution: University of Minnesota

Language: English

Topic: Viral-associated cancers and disorders

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute